Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous sy…
FAIL · Does not pass the screen
50.83 USD
At the last full screen 2026-08-27
Screened 2026-08-27 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
Rapport Therapeutics, Inc. holds its Markdown at $50.83. Elevated stress, defensive posture warranted, held for 161 days.
As held on the ledger · 2026-08-27
Phase
Markdown · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 161 days
Price at the screen
$50.83
Valuation
N/A trailing · -9.72 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.97
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
2.24%
Below 33%
Interest-bearing debt is just 2.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
85.45%
Below 33%
Interest-bearing cash and securities are 85.5% of assets, above the one-third limit.
Fail
Receivables
10.27%
Below 49%
Money owed to the company is 10.3% of assets, under the 49% limit.
Pass
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-08-27 screen. The gold marker is the market price at the same screen. A 16.1% margin of safety to the base estimate.
Third-party analyst targets: 12 covering, consensus Strong Buy. The average target sits +16% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-08-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Early Stage CNS Bets Carry Heavy Failure Odds
Developing medicines for disorders of the brain is like betting on a single path through a maze that most never finish. Rapport is still years from any revenue, posting zero profit margins and a negative return on equity that leaves no margin for the inevitable trial setbacks.
The forward earnings multiple sits in negative territory while the moat remains unknown. Analyst targets cluster around 56 yet the opportunity rating stays at none because the entire case rests on unproven clinical data rather than current cash generation.
Even after clearing the ethical screen the combination of cash burn and binary outcomes makes this one to pass. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
RAPP trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-11Accumulation$50.83+19.3%Entry 5
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 19.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 40% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 167%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (10 analysts) rates it strong buy, with a mean price target of $57.
2026-08-11Accumulation$42.62+11.0%Entry 4
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 11.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 40% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 167%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (10 analysts) rates it strong buy, with a mean price target of $57.
2026-07-18Accumulation$38.40+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is holding around 40% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 167%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (10 analysts) rates it strong buy, with a mean price target of $57.
2026-07-03Accumulation$38.40+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$38.40Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
